Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The amended agreement is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This expansion comes as Datavault AI continues to lead in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. The Acoustic Sciences division features WiSA, ADIO and Sumerian patented technologies for spatial and multichannel wireless high-definition sound transmission, while the Data Science division leverages Web 3.0 and high-performance computing for experiential data perception, valuation and secure monetization.
The platform serves multiple industries including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The global health and wellness market is expanding rapidly, and this agreement positions Datavault AI to capitalize on that growth by enabling new patient-controlled data transaction models. The behavioral healthcare patent portfolio underlying the agreement focuses on medical logistics, IoT population health and AI-driven remote patient monitoring, which are critical areas for improving healthcare outcomes and efficiency.
For more information about Datavault AI and its technologies, visit the company’s newsroom at https://ibn.fm/DVLT and the full press release at https://ibn.fm/vBAxH.
